Health Trials

Secondary Central Nervous System Lymphoma (SCNSL)

3

Review clinical trials related to Secondary Central Nervous System Lymphoma (SCNSL). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Participants needed: 572
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nurix Therapeutics, Inc.Updated: Jul 2, 2026Locations: 62
Eligibility criteria

Age ≥18 years [+5]

Known or suspected active prolymphocytic leukemia or Richter's transformation to... [+17]

Read more
Status: Recruiting

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).

Participants needed: 26
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Jun 11, 2026Locations: 8
Eligibility criteria

>/= 18 years of age on the day of consenting to the study. [+13]

Newly diagnosed PCNSLs or SCNSLs and patients with non-CNS disease are excluded. [+36]

Read more
Status: Recruiting

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

This is a multicenter, open-label, single-arm, prospective clinical study of PD-1 inhibitor combined with rituximab, methotrexate, and orelabrutinib (PD-1i+RMO) in the treatment of newly diagnosed primary central nervous system lymphoma (ND-PCNSL) and secondary central nervous system lymphoma (SCNSL). The primary endpoint is 1-year progression-free survival (PFS).

Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital with Nanjing Medical UniversityUpdated: Feb 13, 2026Locations: 1
Eligibility criteria

Hematology: Absolute neutrophil count (ANC) ≥ 1.0×10⁹/L, platelet count (PLT) ≥... [+5]

Presence of disease involvement outside the central nervous system. [+19]

Read more